Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances Wages, Salaries and Other

Neuroone Medical Technologies (NMTC) Long-Term Debt Issuances (2016 - 2020)

Neuroone Medical Technologies filings provide 5 years of Long-Term Debt Issuances readings, the most recent being $5.0 million for Q4 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $5.0 million in Q4 2020 year-over-year; TTM through Dec 2020 was $142427.0, a N/A change, with the full-year FY2020 number at $8.4 million, changed N/A from a year prior.
Long-Term Debt Issuances hit $5.0 million in Q4 2020 for Neuroone Medical Technologies, up from -$534201.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $5.0 million in Q4 2020 to a low of -$4.5 million in Q2 2017.
Median Long-Term Debt Issuances over the past 3 years was $8210.0 (2016), compared with a mean of $23361.9.
Biggest five-year swings in Long-Term Debt Issuances: surged 243.3% in 2016 and later tumbled 55103.64% in 2017.
Neuroone Medical Technologies' Long-Term Debt Issuances stood at $21106.0 in 2016, then plummeted by 2631.04% to -$534201.0 in 2017, then surged by 1035.98% to $5.0 million in 2020.
The last three reported values for Long-Term Debt Issuances were $5.0 million (Q4 2020), -$534201.0 (Q3 2017), and -$4.5 million (Q2 2017) per Business Quant data.